DYN - Dyne Therapeutics Inc logo

DYN

Dyne Therapeutics Inc

Rev —top 1%5Y
Hold

Dyne Therapeutics develops therapeutics for genetically driven neuromuscular diseases, focusing on conditions like myotonic dystrophy and Duchenne muscular dystrophy. Its FORCE platform aims to deliver disease-modifying treatments targeting muscle and CNS.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $1,510today

Score Overview

1 Year
Score
Net Growth-16.40%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-247.92%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-6x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Dyne Therapeutics Inc fundamental performance

Across Dyne Therapeutics Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 58M to -$ 446M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 26.17
1 Year2025-08-12
$ 11.62125.22%
5 Years2021-08-12
$ 17.3351.01%
All Time2020-09-17
$ 23.909.50%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 519M$ 898M
2025$ 0.00-$ 446M$ 1.11B
2024$ 0.00-$ 317M$ 642M
2023$ 0.00-$ 235M$ 123M
2022$ 0.00-$ 165M$ 256M
2021$ 0.00-$ 149M$ 376M
IPO2020$ 0.00-$ 58M$ 345M

Explore beyond DYN

You're looking at Dyne Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies